Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M4344 plus Niraparib in Advanced Solid Tumors and Breast Cancer
NCT04655183Phase 2Withdrawn
- Sponsor
- EMD Serono
- Start
- Dec 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gartisertib in solid tumor (advanced stage), breast cancer, sponsored by EMD Serono. Planned start Dec 2020; status: withdrawn.
02
Drugs
gartisertib
03
Conditions
solid tumor (advanced stage)breast cancer
Beyond the preview
Go deeper on NCT04655183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655183.